Human Recombinant MAP3K1, Active protein, GST Tag (V2LY-0526-LY5428)

Kuo, S. H., Wei, M. F., Lee, Y. H., Lin, J. C., Yang, W. C., Yang, S. Y., & Huang, C. S. (2023). MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer. Cellular Oncology, 1-22.

Aziz, M. A., & Islam, M. S. (2023). MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis. Cancer Reports, 6(1), e1773.

Napoleon, J. V., Sagar, S., Kubica, S. P., Boghean, L., Kour, S., King, H. M., ... & Natarajan, A. (2022). Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences, 119(18), e2115071119.

Li, C., Zhang, G., Wang, Y., Chen, B., Li, K., Cao, L., ... & Liao, N. (2022). Spectrum of MAP3K1 mutations in breast cancer is luminal subtype‑predominant and related to prognosis. Oncology Letters, 23(2), 1-12.

Wang, J., Kimura, E., Mongan, M., & Xia, Y. (2021). Genetic Control of MAP3K1 in Eye Development and Sex Differentiation. Cells, 11(1), 34.

Al Shamsi, A., Al Hassani, N., Hamchou, M., Almazrouei, R., & Mhanni, A. (2020). A novel missense heterozygous mutation in MAP3K1 gene causes 46, XY disorder of sex development: case report and literature review. Molecular Genetics & Genomic Medicine, 8(11), e1514.

Wang, J., Zuo, J., Wahafu, A., Wang, M. D., Li, R. C., & Xie, W. F. (2020). Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma. CNS neuroscience & therapeutics, 26(3), 297-308.

Carene, D., Tran-Dien, A., Lemonnier, J., Dalenc, F., Levy, C., Pierga, J. Y., ... & Michiels, S. (2020). Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. Breast Cancer Research and Treatment, 179(2), 387-401.

Nixon, M. J., Formisano, L., Mayer, I. A., Estrada, M. V., González-Ericsson, P. I., Isakoff, S. J., ... & Balko, J. M. (2019). PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. NPJ Breast Cancer, 5(1), 31.

Chamberlin, A., Huether, R., Machado, A. Z., Groden, M., Liu, H. M., Upadhyay, K., ... & Ostrer, H. (2019). Mutations in MAP3K1 that cause 46, XY disorders of sex development disrupt distinct structural domains in the protein. Human molecular genetics, 28(10), 1620-1628.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols